SRC proteins can link receptor tyrosine kinases to critical downstream oncogenic pathways such asPI3K/PTEN/Akt, STATs, and Ras/Raf/ERK. Regulation of these key pathways allows SRC to control cellulargrowth and proliferation, survival, invasion, and angiogenesis. Based on the importance of EGFR signalingin lung cancer and the known cooperation between EGFR and SRC proteins, we evaluated the effectivenessof novel SRC inhibitors in lung cancer cell lines with defined EGFR status. SRC inhibition reduces mutantEGFR lung cancer cell viability through the induction of apoptosis while having no significant apoptotic effecton cell lines with wildtype EGFR. The induction of apoptosis in EGFR mutant cell lines corresponds todownregulation of activated Akt and Stat3 survival proteins. In cell lines without EGFR mutation, SRCinhibition reduces cyclin D and increases p27 protein levels with a corresponding G1 cell cycle arrest. SRCinhibition also inhibits activated FAK and inhibits lung cancer cell invasion. These data demonstrate thatnovel SRC inhibitors could be effective therapy for patients with lung cancers, especially those driven bymutant EGFR proteins. The goal of this research proposal is to further characterize the effect of novel SRCkinase inhibitors in lung cancer cells.
In specific aim 1, we will characterize the effect of SRC inhibitors onapoptosis and growth inhibition in lung cancer cells with defined EGFR status. We will evaluate the effectson key downstream pathways that control apoptosis and cell growth such as PI3K/PTEN/Akt and STATs.We will evaluate the effect of combined EGFR and SRC tyrosine kinase inhibitors on apoptosis and growthinhibition. Novel biomarkers will be identified through phospho-proteomics.
In specific aim 2, we willevaluate the effect of SRC inhibition on tumor growth in vivo in lung cancer xenograft models withcorresponding biomarker analysis. We plan to test the hypothesis that SRC inhibitor treatment of lungcancer xenografts with EGFR mutation will undergo tumor regression through enhanced apoptosis whiletreatment of xenografts with wildtype EGFR will result in growth inhibition. Biomarkers of response definedin the above aim will be further validated in these models.
In specific aim 3, we will conduct an investigatorinitiatedpatient-based phase II trial of erlotinib &dasatinib in previously treated NSCLC along withbiomolecular analysis based on mechanisms defined in Aims 1&2.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA119997-01A2
Application #
7449096
Study Section
Special Emphasis Panel (ZCA1-GRB-I (J1))
Project Start
2008-09-15
Project End
2012-08-31
Budget Start
2008-09-15
Budget End
2009-08-31
Support Year
1
Fiscal Year
2008
Total Cost
$187,310
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Li, Yafang; Xiao, Xiangjun; Han, Younghun et al. (2018) Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population. Carcinogenesis 39:336-346
Li, Qian; Balagurunathan, Yoganand; Liu, Ying et al. (2018) Comparison Between Radiological Semantic Features and Lung-RADS in Predicting Malignancy of Screen-Detected Lung Nodules in the National Lung Screening Trial. Clin Lung Cancer 19:148-156.e3
Ctortecka, Claudia; Palve, Vinayak; Kuenzi, Brent M et al. (2018) Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells. Mol Cell Proteomics 17:2434-2447
Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221
Rosenberger, Albert; Hung, Rayjean J; Christiani, David C et al. (2018) Genetic modifiers of radon-induced lung cancer risk: a genome-wide interaction study in former uranium miners. Int Arch Occup Environ Health 91:937-950
Dai, Juncheng; Li, Zhihua; Amos, Christopher I et al. (2018) Systematic analyses of regulatory variants in DNase I hypersensitive sites identified two novel lung cancer susceptibility loci. Carcinogenesis :
Ferreiro-Iglesias, Aida; Lesseur, Corina; McKay, James et al. (2018) Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity. Nat Commun 9:3927
Li, Qian; Kim, Jongphil; Balagurunathan, Yoganand et al. (2017) Imaging features from pretreatment CT scans are associated with clinical outcomes in nonsmall-cell lung cancer patients treated with stereotactic body radiotherapy. Med Phys 44:4341-4349
Gimbrone, Nicholas T; Sarcar, Bhaswati; Gordian, Edna R et al. (2017) Somatic Mutations and Ancestry Markers in Hispanic Lung Cancer Patients. J Thorac Oncol 12:1851-1856
Lohavanichbutr, Pawadee; Sakoda, Lori C; Amos, Christopher I et al. (2017) Common TDP1 Polymorphisms in Relation to Survival among Small Cell Lung Cancer Patients: A Multicenter Study from the International Lung Cancer Consortium. Clin Cancer Res 23:7550-7557

Showing the most recent 10 out of 108 publications